Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 6
2013 1
2014 6
2015 6
2016 5
2017 3
2018 7
2019 10
2020 13
2021 11
2022 7
2023 11
2024 6
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, Georges S, Ellers-Lenz B, Shah P, Güzel G, Nghiem P. D'Angelo SP, et al. Among authors: prinzi n. J Immunother Cancer. 2021 Jul;9(7):e002646. doi: 10.1136/jitc-2021-002646. J Immunother Cancer. 2021. PMID: 34301810 Free PMC article. Clinical Trial.
Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi N, Corti F, Torchio M, Niger M, Antista M, Pagani F, Beninato T, Pulice I, Rossi RE, Coppa J, Cascella T, Giacomelli L, Di Bartolomeo M, Milione M, de Braud F, Pusceddu S. Prinzi N, et al. Tumori. 2022 Dec;108(6):526-540. doi: 10.1177/03008916221078621. Epub 2022 May 20. Tumori. 2022. PMID: 35593402 Review.
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregni E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C. Pusceddu S, et al. Among authors: prinzi n. J Hematol Oncol. 2023 Dec 14;16(1):119. doi: 10.1186/s13045-023-01510-9. J Hematol Oncol. 2023. PMID: 38098114 Free PMC article. Clinical Trial.
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, Morano F, Niger M, Maccauro M, Milione M, de Braud F, Pietrantonio F, Pusceddu S. Nasca V, et al. Among authors: prinzi n. Eur J Cancer. 2024 Sep;209:114276. doi: 10.1016/j.ejca.2024.114276. Epub 2024 Aug 9. Eur J Cancer. 2024. PMID: 39128186 Clinical Trial.
Pathophysiology and treatment of exercise-associated hyponatremia.
Altieri B, Aini I, Cannavale G, Magnelli C, Mancini C, Zamponi V, Isidori AM, Colao A, Faggiano A, Peri A; NIKE group. Altieri B, et al. J Endocrinol Invest. 2025 Sep 6. doi: 10.1007/s40618-025-02673-7. Online ahead of print. J Endocrinol Invest. 2025. PMID: 40913680 Review.
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma.
Laganà M, Habra MA, Remde H, Almeida MQ, Cosentini D, Pusceddu S, Grana CM, Corssmit EPM, Bongiovanni A, De Filpo G, Lim ES, Zamparini M, Grisanti S, Deutschbein T, Fassnacht M, Fagundes GFC, Pereira MAA, Oldani S, Rota S, Prinzi N, Jimenez C, Berruti A. Laganà M, et al. Among authors: prinzi n. Eur J Cancer. 2024 Sep;208:114122. doi: 10.1016/j.ejca.2024.114122. Epub 2024 Jul 3. Eur J Cancer. 2024. PMID: 39047533 Free article.
Fertility drugs, reproductive strategies and ovarian cancer risk.
Tomao F, Lo Russo G, Spinelli GP, Stati V, Prete AA, Prinzi N, Sinjari M, Vici P, Papa A, Chiotti MS, Benedetti Panici P, Tomao S. Tomao F, et al. Among authors: prinzi n. J Ovarian Res. 2014 May 8;7:51. doi: 10.1186/1757-2215-7-51. eCollection 2014. J Ovarian Res. 2014. PMID: 24829615 Free PMC article. Review.
Nutritional status and follicular-derived thyroid cancer: An update.
Barrea L, Gallo M, Ruggeri RM, Giacinto PD, Sesti F, Prinzi N, Adinolfi V, Barucca V, Renzelli V, Muscogiuri G, Colao A, Baldelli R; E.O.L.O. Group. Barrea L, et al. Among authors: prinzi n. Crit Rev Food Sci Nutr. 2021;61(1):25-59. doi: 10.1080/10408398.2020.1714542. Epub 2020 Jan 30. Crit Rev Food Sci Nutr. 2021. PMID: 31997660 Review.
Update on medical treatment of small intestinal neuroendocrine tumors.
Pusceddu S, Femia D, Lo Russo G, Ortolani S, Milione M, Maccauro M, Vernieri C, Prinzi N, Concas L, Leuzzi L, De Braud F, Buzzoni R. Pusceddu S, et al. Among authors: prinzi n. Expert Rev Anticancer Ther. 2016 Sep;16(9):969-76. doi: 10.1080/14737140.2016.1207534. Epub 2016 Jul 13. Expert Rev Anticancer Ther. 2016. PMID: 27353232 Review.
Digestive MiNENs: Could histological classification and molecular characterization drive clinical outcome and therapeutic approach?
Cattaneo L, Centonze G, Sabella G, Lagano V, Angerilli V, Pardo C, Bertani E, Spada F, Prinzi N, Pusceddu S, Fassan M, Fazio N, Milione M. Cattaneo L, et al. Among authors: prinzi n. Crit Rev Oncol Hematol. 2023 Aug;188:104044. doi: 10.1016/j.critrevonc.2023.104044. Epub 2023 Jun 1. Crit Rev Oncol Hematol. 2023. PMID: 37268174 Review.
81 results